Atherosclerotic lesions in humans and other animal models of the disease are associated with areas of increased vasa vasasorum that proliferate and extend into the intimal layer. Published data suggests these plaque capillaries may be markers of cell proliferation, promote inflammatory cell entry into lesions, or may be involved in plaque hemorrhage and rupture that can initiate a myocardial infarction or stroke. In recent studies, endotheljal cell inhibitors reduced intimal neovascularization and plaque growth in ApoE-deficient mice, which suggest plaque angiogenesis contributes to the progression of atherosclerosis. Due to its association with disease progression and the development of acute ischemic complications, it is relevant to understand the mechanisms and to identify the endogenous factors that regulate plaque angiogenesis. Intimal neovascularization has been documented in advanced lesions of ApoE-/- mice. Atherosclerotic lesions will be tested in a serum-free in vitro assay of plaque-induced sprout formation to characterize the relative biologic activities that stimulate angiogenesis in lesions. ApoE-/- mice will be treated with specific antagonists of these endogenous factors to determine if they regulate plaque angiogenesis and lesion growth in vivo. Endostatin an endogenous inhibitor of angiogenesis is retained in the medial layer of the aorta. ApoE-/- mice will be crossed with mice deficient in collagen XVlll/endostatjn to determine if loss of an endogenous inhibitor of angiogenesis in the aorta will enhance intimal neovascularization and plaque growth. Atherosclerotic lesions treated with different angiogenesis inhibitors will be evaluated to determine the functional consequences of these agents on the cell content and turnover of lesions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL067255-01
Application #
6321448
Study Section
Pathology A Study Section (PTHA)
Program Officer
Goldman, Stephen
Project Start
2001-08-01
Project End
2005-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
1
Fiscal Year
2001
Total Cost
$292,220
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Bishop, Joseph R; Passos-Bueno, Maria Rita; Fong, Loren et al. (2010) Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans. PLoS One 5:e13919
Zhang, Yali; Naggar, Jack C; Welzig, C Michael et al. (2009) Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 29:1764-71
Zeng, Xiaokun; Chen, Joshua; Miller, Yury I et al. (2005) Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. J Lipid Res 46:1849-59
Moulton, Karen S; Olsen, Bjorn R; Sonn, Silvia et al. (2004) Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 110:1330-6
Yu, Ying; Moulton, Karen S; Khan, Mohamed K et al. (2004) E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci U S A 101:8005-10
Moulton, K S (2002) Plaque angiogenesis: its functions and regulation. Cold Spring Harb Symp Quant Biol 67:471-82